[{"id":"50192133-c8e8-4b6f-9edf-895d64f162f6","acronym":"","url":"https://clinicaltrials.gov/study/NCT05995041","created_at":"2023-08-16T16:08:27.797Z","updated_at":"2024-07-02T16:35:33.734Z","phase":"Phase 1","brief_title":"Universal CAR-T Cells Targeting AML","source_id_and_acronym":"NCT05995041","lead_sponsor":"Shenzhen Geno-Immune Medical Institute","biomarkers":" CD38 • CD33 • IL3RA","pipe":" | ","alterations":" CD123 expression","tags":["CD38 • CD33 • IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CLL-1, CD33, CD38 and/or CD123-specific universal CAR- T"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 10/31/2023","start_date":" 10/31/2023","primary_txt":" Primary completion: 09/30/2026","primary_completion_date":" 09/30/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2023-10-12"}]